-
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-09 V. Michael Holers, Kristen M. Demoruelle, Jane H. Buckner, Eddie A. James, Gary S. Firestein, William H. Robinson, Allen C. Steere, Fan Zhang, Jill M. Norris, Kristine A. Kuhn, Kevin D. Deane
-
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13 Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-09 Mehrdad Pazhouhandeh, Di Yu
-
JAK inhibitor selectivity: new opportunities, better drugs? Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-09 Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, John J. O’Shea, Olli Silvennoinen, Massimo Gadina
-
An interdisciplinary perspective on peripheral drivers of pain in rheumatoid arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-06 Zoe Rutter-Locher, Bruce W. Kirkham, Kirsty Bannister, David L. Bennett, Christopher D. Buckley, Leonie S. Taams, Franziska Denk
-
Molecular mimicry links SARS-CoV-2 infection and MIS-C Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-05 Jessica McHugh
Researchers have identified a mechanistic link between SARS-CoV-2 infection and multisystem inflammatory syndrome in children, providing evidence for the involvement of molecular mimicry.
-
Helicobacter pylori-induced citrullination linked to RA exacerbation Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-04 Holly Webster
New findings reveal a potential mechanism by which Helicobacter pylori exacerbates rheumatoid arthritis
-
Guiding ILD management in systemic autoimmune rheumatic diseases Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-04 Fabrizio Luppi, Marco Sebastiani
The first guidelines for the screening, monitoring and treatment of interstitial lung disease (ILD) in patients with systemic autoimmune rheumatic diseases (SARDs) are now available after a major multidisciplinary effort by the ACR and the American College of Chest Physicians. These guidelines demonstrate that multidisciplinary collaborations can improve SARD-ILD management.
-
Systemic lupus erythematosus genetics: insights into pathogenesis and implications for therapy Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-04 Yogita Ghodke-Puranik, Mikhail Olferiev, Mary K. Crow
-
The immune health metric as an indicator of health and disease Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-02 Satoshi Kubo, Yoshiya Tanaka
-
Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-02 Maya H. Buch, Ziad Mallat, Marc R. Dweck, Jason M. Tarkin, Declan P. O’Regan, Vanessa Ferreira, Taryn Youngstein, Sven Plein
-
Is X chromosome inactivation a cause or effect of SLE? Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-09-02 R. Hal Scofield, Valerie M. Lewis
Autoimmune diseases such as systemic lupus erythematosus preferentially affect women, and multiple hypotheses are under investigation to elucidate this phenomenon. Emerging research suggests that multiple pathophysiological mechanisms and pathways are likely involved, including several that involve the X chromosome, but is skewing of X chromosome inactivation one of them?
-
Macrophage-coated nanocarriers for gouty arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-08-23 Holly Webster
In a new study, researchers use M2 macrophage exosomes and membranes to disguise a tri-drug-carrying nanosystem that reduces inflammation and urate levels in rats with gouty arthritis.
-
Advancing equity in genomic medicine for rheumatology Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-08-22 Roberto Díaz-Peña, Olufemi Adelowo
Increasing diversity in genomic studies is essential to advance precision medicine and health equity in rheumatic diseases. Addressing structural and logistical barriers to include underrepresented populations, particularly in Africa and Latin America, could improve our understanding of rheumatic diseases and lead to better healthcare outcomes for all.
-
PDZK1 downregulation linked to mitochondrial dysfunction in OA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-08-20 Maria Papatriantafyllou
The PDZ domain-containing scaffold protein PDZK1 is downregulated in osteoarthritic chondrocytes and is linked to mitochondrial dysfunction and chondrocyte senescence.
-
Ion channels in osteoarthritis: emerging roles and potential targets Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-08-09 Renpeng Zhou, Wenyu Fu, Dmytro Vasylyev, Stephen G. Waxman, Chuan-ju Liu
-
Behavioural therapy app for fibromyalgia Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-08-08 Sarah Onuora
Cognitive behavioural therapy, including acceptance and commitment therapy (ACT), is recommended as part of a multimodal approach to the management of fibromyalgia. The phase III PROSPER-FM trial has now shown that a self-guided smartphone-based ACT programme is safe and improves clinical outcomes in adults with fibromyalgia. ACT aims to enhance patients’ capacity to adapt to challenges and achieve
-
The role of obesity and adipose tissue dysfunction in osteoarthritis pain Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-08-07 Marie Binvignat, Jérémie Sellam, Francis Berenbaum, David T. Felson
-
The past 25 years in paediatric rheumatology: insights from monogenic diseases Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-08-07 Seza Ozen, Ivona Aksentijevich
-
Advancements and challenges in CAR T cell therapy in autoimmune diseases Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-08-06 Georg Schett, Fabian Müller, Jule Taubmann, Andreas Mackensen, Wei Wang, Rich A. Furie, Ralf Gold, Aiden Haghikia, Peter A. Merkel, Roberto Caricchio, Maria-Antonietta D’Agostino, Franco Locatelli, Carl H. June, Dimitrios Mougiakakos
-
Shedding light onto the immunometabolic effects of glucocorticoids Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-08-01 Luis M. Franco
-
Off-the-shelf CAR T cells for refractory autoimmunity Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-29 Maria Papatriantafyllou
Early data indicate that allogeneic CAR T cell therapy targeting B cells is a scalable and safe therapeutic strategy in refractory autoimmunity.
-
UNC93B1 variants promote SLE via TLR activation Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-26 Holly Webster
Two studies have identified variants of UNC93B1 that are associated with enhanced TLR7 and TLR8 activity and the development of systemic lupus erythematosus.
-
Integrin signalling in joint development, homeostasis and osteoarthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-16 Michael Z. Miao, Janice S. Lee, Kenneth M. Yamada, Richard F. Loeser
-
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-11 Megan P. Leask, Tania O. Crișan, Aichang Ji, Hirotaka Matsuo, Anna Köttgen, Tony R. Merriman
-
Itaconate targets fibroblast-like synoviocytes in RA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-10 Sarah Onuora
Treatment with the endogenous metabolite itaconate induced phenotypic and metabolic changes in fibroblast-like synoviocytes and reduced the severity of arthritis in an animal model.
-
Update on the pathophysiology and treatment of primary Sjögren syndrome Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-09 Chiara Baldini, Giovanni Fulvio, Gaetano La Rocca, Francesco Ferro
-
Pathogenic antibodies target stromal antigens in RA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-08 Jessica McHugh
New findings identify HSP60 and other synovial stromal-derived autoantigens as targets for pathogenic autoantibodies, exacerbating arthritis and serving as potential biomarkers.
-
Integrin-mediated ILC2 adhesion protects against lupus nephritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-08 Jessica McHugh
Type 2 innate lymphoid cells protect against kidney inflammation in lupus nephritis, and enhancing their adhesion via integrin α4β7 upregulation, particularly through IL-33 treatment, could be a promising therapeutic approach.
-
How muscle influences bone health Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-05 Maria Papatriantafyllou
FNIP1- and TFEB-dependent secretion of IGF2 by dystrophic muscles contributes to muscle–bone crosstalk.
-
Publisher Correction: IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-07-01 Lori Broderick,Hal M Hoffman
-
Mitophagy as a link between ECM stiffness and chondrocyte senescence Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-21 Maria Papatriantafyllou
Ageing and excessive mechanical strain on the articular cartilage have both been associated with the development of knee osteoarthritis (OA). Cartilage degeneration in OA involves a senescent phenotype of chondrocytes, as well as modifications of the extracellular matrix (ECM). Research published in Bone Research investigates how mechanical signals in the form of altered ECM stiffness might lead to
-
Platelets in Kawasaki disease: mediators of vascular inflammation Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-17 Magali Noval Rivas, Begüm Kocatürk, Bernardo S. Franklin, Moshe Arditi
-
BiTEing refractory RA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-10 Jessica McHugh
The bispecific T cell engager (BiTE) blinatumomab showed promising clinical efficacy in a pilot study of six patients with multidrug-resistant rheumatoid arthritis.
-
Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-10 Christian D. DeMoya, Anisha Joenathan, Taylor B. Lawson, David T. Felson, Thomas P. Schaer, Manish Bais, Michael B. Albro, Janne Mäkelä, Brian D. Snyder, Mark W. Grinstaff
-
The peculiar features, diversity and impact of citrulline-reactive autoantibodies Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-10 Bruno Raposo, Lars Klareskog, William H. Robinson, Vivianne Malmström, Caroline Grönwall
-
Wearable device for RA management? Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-05 Maria Papatriantafyllou
A wearable smart device that uses reconfigurable electronics and conductive polymer-based microneedles was able to monitor inflammation and provide transdermal drug delivery and electrical stimulation in a rat model of arthritis.
-
COVID-19 linked to rise in anti-MDA5 autoimmunity Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-05 Jessica McHugh
Researchers have introduced the term ‘MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic’ (MIP-C) to describe cases of MDA5 autoimmunity that surged during the COVID-19 pandemic.
-
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-05 Sarah Onuora
New research provides a potential explanation for why long-term sclerostin neutralization leads to continued bone mass gain, despite attenuation of its short-term effects on bone formation.
-
Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-06-03 Frank Buttgereit, Andriko Palmowski, Milena Bond, Giovanni Adami, Christian Dejaco
-
Clarity for the language of race, ethnicity and genetic ancestry in rheumatology Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-31 Paula S. Ramos, S. Sam Lim
As the pace of genetic discovery has accelerated, so too has the need for clinicians and researchers to acknowledge and understand the impact of language in scientific publications. The use of inaccurate language contributes to systemic bias and eugenic ideologies that remain pervasive in biomedical science, including in rheumatology.
-
Two sides of management recommendations for psoriatic arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-21 Ennio Lubrano, Fabio Massimo Perrotta
Guidelines for the management of psoriatic arthritis (PsA) need to undergo revision to take on board new evidence, particularly in relation to therapeutics. In March 2024, EULAR published updated recommendations for the pharmacological treatment of PsA, and an expert group published consensus statements intended to complement existing guidelines.
-
Clinical phenotypes, molecular endotypes and theratypes in OA therapeutic development Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-17 Ali Mobasheri, Richard Loeser
-
Can transcriptomics guide the management of SLE-associated APS? Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-16 Jason S. Knight, Maria G. Tektonidou
The management of antiphospholipid syndrome is hindered by heterogeneous clinical presentations. Whole-blood transcriptomics have the potential to identify previously unknown disease endotypes, which could inform new treatment strategies. However, such hypothesis-generating data must still account for the results of randomized clinical trials, such as those focused on direct oral anticoagulants in
-
Recent advancements in cartilage tissue engineering innovation and translation Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-13 Rachel C. Nordberg, Benjamin J. Bielajew, Takumi Takahashi, Shuyan Dai, Jerry C. Hu, Kyriacos A. Athanasiou
-
Bone-modifying drugs slow OA progression Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-07 Sarah Onuora
Drugs used to treat osteoporosis could slow the progression of osteoarthritis, according to the findings of a study in mice.
-
Adropin inhibits fibrosis in SSc Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-03 Robert Phillips
The peptide hormone adropin, which is downregulated in dermal fibroblasts in patients with systemic sclerosis (SSc), inhibits TGFβ-mediated fibrosis in in vitro and ex vivo models of human skin, and has potential for the treatment of SSc.
-
Rethinking antiphospholipid syndrome to guide future management and research Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-03 Jason S. Knight, Doruk Erkan
Antiphospholipid syndrome (APS) consists of thrombotic, non-thrombotic and obstetric clinical manifestations developing in individuals with persistent antiphospholipid antibodies (aPL). Although researchers have made progress in characterizing different clinical phenotypes of aPL-positive people, the current approach to clinical management is still mostly based on a ‘one size fits all’ strategy, which
-
Relapsing polychondritis: clinical updates and new differential diagnoses Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-02 Philippe Mertz, Nathalie Costedoat-Chalumeau, Marcela A. Ferrada, Guillaume Moulis, Arsène Mekinian, Peter C. Grayson, Laurent Arnaud
-
Granzyme serine proteases in inflammation and rheumatic diseases Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-04-30 Alexandre Aubert, Karen Jung, Sho Hiroyasu, Julian Pardo, David J. Granville
-
Author Correction: Proposals for the rheumatological use of JAK inhibitors. Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-01 Francesco Ciccia,Roberto Caporali
-
Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups. Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-01 Margherita Giannini,Léa Debrut,Benoit Nespola,Michel Velten,Bernard Geny,Jean Sibilia,Alain Meyer
-
Reply to: Current classification criteria underestimate the incidence of idiopathic inflammatory myopathies by ignoring subgroups. Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-05-01 Thomas Khoo,James B Lilleker,Bernard Yu-Hor Thong,Valérie Leclair,Janine A Lamb,Hector Chinoy
-
Treat-to-target or treat-to-dissolve strategy to improve gout treatment Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-04-26 Pascal Richette, Nicola Dalbeth
Medication adherence in gout is low, and discontinuation of urate-lowering therapy puts patients at risk of flares and cardiovascular events. A strategy to regularly monitor serum urate levels and the dissolution of urate deposits (particularly if visualized by patients) might encourage adherence in the long term.
-
Advancing precision rheumatology through tissue and blood profiling Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-04-12 George D. Kalliolias, Athanasios G. Papavassiliou
-
Molecular biomarker approaches to prevention of post-traumatic osteoarthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-04-11 Virginia Byers Kraus, Ming-Feng Hsueh
-
Joint-specific memory, resident memory T cells and the rolling window of opportunity in arthritis Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-04-10 Margaret H. Chang, Robert C. Fuhlbrigge, Peter A. Nigrovic
-
Benralizumab noninferior to mepolizumab for EGPA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-04-09 Sarah Onuora
In a head-to-head phase III trial of two drugs that target IL-5 or its receptor, benralizumab was noninferior to mepolizumab for the induction of remission in patients with eosinophilic granulomatosis with polyangiitis.
-
Time for a new approach to drug development for rare systemic autoinflammatory diseases Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-04-02 Natalie M. Zitoun, Erkan Demirkaya, Raphaela Goldbach-Mansky, Micol Romano
Despite the transformative potential of treatments for systemic autoinflammatory diseases, these conditions remain underfunded and understudied. Urgent, coordinated action among stakeholders is needed to overcome regulatory and research barriers, as is innovation and advocacy for the development of effective therapies for these rare diseases.
-
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-03-27 Vanessa L. Kronzer, Jeffrey A. Sparks, Soumya Raychaudhuri, James R. Cerhan
-
Nanoparticle-based pazopanib shows promise in OA Nat. Rev. Rheumatol. (IF 29.4) Pub Date : 2024-03-19 Rebecca Kelsey
A nanoparticle-based formulation of the anticancer drug pazopanib, which inhibits VEGFR1 and VEGFR2, shows promise as a disease-modifying drug for osteoarthritis.